Foresite Capital Management III’s Aimmune Therapeutics AIMT Stock Holding History

Foresite Capital Management III’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-611,893	Closed	-$12.8M	–	12
2019 Q3	$12.8M	Sell	611,893 -35,361	-5%	-$722K	4.89%	7
2019 Q2	$13.5M	Hold	647,254	–	–	4.42%	7
2019 Q1	$14.5M	Sell	647,254 -62,568	-9%	-$1.47M	3.77%	9
2018 Q4	$17M	Sell	709,822 -91,418	-11%	-$2.37M	5.58%	7
2018 Q3	$21.9M	Sell	801,240 -49,973	-6%	-$1.41M	4.82%	6
2018 Q2	$22.9M	Sell	851,213 -83,807	-9%	-$2.56M	4.93%	6
2018 Q1	$29.8M	Buy	935,020 +170,196	+22%	+$5.99M	6.49%	7
2017 Q4	$28.9M	Sell	764,824 -147,177	-16%	-$4.75M	8.12%	5
2017 Q3	$22.6M	Hold	912,001	–	–	6.23%	6
2017 Q2	$18.8M	Hold	912,001	–	–	6.13%	5
2017 Q1	$19.8M	Buy	912,001 +8,111	+0.9%	+$166K	7.61%	4
2016 Q4	$18.5M	Sell	903,890 -31,130	-3%	-$636K	8.03%	4
2016 Q3	$14M	Buy	935,020 +700,000	+298%	+$9.45M	6.56%	4
2016 Q2	$2.54M	Sell	235,020 -120,000	-34%	-$1.63M	1.74%	14
2016 Q1	$4.81M	Hold	355,020	–	–	3.72%	9
2015 Q4	$6.55M	Buy	+355,020	New	+$6.57M	5.81%	6

Other funds holding AIMT

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Foresite Capital Management III's AIMT Position: Q4 2019 in Review

Foresite Capital Management III sold out of Aimmune Therapeutics (AIMT) in Q4 2019, closing a stake of 611,893 shares — an estimated $12.8M sold.

Foresite Capital Management III first reported a position in AIMT in Q4 2015 and held it in 16 quarters. The position peaked at $29.8M in Q1 2018. 155 funds tracked by Wall St. Rank hold AIMT as of Q4 2019.

Foresite Capital Management III reported no remaining Aimmune Therapeutics position as of Q4 2019 after selling out during the quarter.
Foresite Capital Management III sold 611,893 Aimmune Therapeutics shares in Q4 2019, an estimated $12.8M.
Foresite Capital Management III first reported a position in Aimmune Therapeutics in Q4 2015 and held it in 16 quarters.
Foresite Capital Management III's Aimmune Therapeutics position peaked at $29.8M in Q1 2018.
155 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2019.

Based on Foresite Capital Management III's 13F filing for Q4 2019, filed 14 Feb 2020.